DehydraTECH-CBD
Hypertension
Key Facts
About Lexaria Bioscience
Lexaria Bioscience is a micro-cap biotech focused on commercializing its proprietary DehydraTECH™ drug delivery platform. The company's mission is to improve the performance of existing and new oral pharmaceuticals, particularly fat-soluble molecules, by increasing their bioavailability and onset speed. Its strategy is purely licensing-based, partnering with established pharmaceutical and consumer product companies to integrate DehydraTECH into their pipelines. Key achievements include a robust global patent portfolio, positive human clinical data across multiple drug classes, and a lean operational structure that extends its capital runway.
View full company profileTherapeutic Areas
Other Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Norliqva® (Amlodipine Oral Solution) | CMP Pharma | Approved |
| Renal & Hepatic Denervation for Hypertension | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| Peregrine System Renal Denervation | Ablative Solutions | Phase 3 |
| Hypertension Program | Closed Loop Medicine | Development |
| GMRx2 | George Medicines | Phase 3 |
| High Blood Pressure Study | West Coast Research | Phase 3/4 |
| Zilebesiran (ALN-AGT) | Alnylam Pharmaceuticals | Phase 3 |